Optimal management of platelet function after coronary stenting.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Coronary stenting can cause vessel damage, leading to platelet activation and stent thrombosis.
• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard post-stenting to prevent complications.
• Current DAPT regimens have limitations, including delayed onset of action and incomplete protection in some patients.

Purpose of the Study:

• To review the role of antiplatelet therapy in preventing stent thrombosis after coronary stenting.
• To discuss the limitations of current dual antiplatelet therapy (aspirin and clopidogrel).
• To explore emerging antiplatelet strategies for improved outcomes.

Main Methods:

• Review of current literature on antiplatelet therapy after coronary stenting.
• Analysis of complications associated with stent thrombosis.
• Evaluation of new antiplatelet agents and combination therapies.

Main Results:

• DAPT with aspirin and clopidogrel reduces major adverse cardiac events but does not eliminate stent thrombosis (occurs in ~1% of patients).
• Stent thrombosis, though rare, carries a high mortality rate (up to 45%) and is often associated with acute coronary syndrome.
• Clopidogrel's efficacy is dependent on achieving adequate platelet inhibition, which can be affected by loading dose and timing.

Conclusions:

• Despite DAPT, a significant number of patients remain inadequately protected from thrombotic events.
• Newer antiplatelet agents (Prasugrel, Cangrelor, AZD6140) and combination therapies (e.g., aspirin, clopidogrel, cilostazol) show promise in clinical trials.
• Further research and clinical evaluation are needed to optimize antiplatelet strategies for patients undergoing coronary stenting.